Lunai Bioworks: A Strategic Overview for Shareholders in 2026

Dear Esteemed Shareholders,

As we move through 2026, it is vital to share the progress Lunai Bioworks (NASDAQ: LNAI) has made in establishing itself as a leader in the biotechnology space, particularly at the crossroads of artificial intelligence and national security. Our recent advancements not only align with our mission but also open numerous avenues for creating value for our shareholders.

Establishing a Uniquely Strategic Position in Biodefense

In April 2026, we marked a significant milestone by securing our first revenue-generating contract—a multi-year collaboration with BioSymetrics to implement our AI-enabled platform dedicated to chemical threat assessments for the U.S. government. This collaboration signifies not just a research endeavor, but a robust commercial partnership.

Furthermore, we have initiated the Pathfinder Consortium—a collaborative network that includes top institutions such as Harvard University and Brigham and Women’s Hospital. This alliance not only enhances our scientific credibility but also underscores the importance of our initiatives in strengthening national security.

Looking towards the future, we recognize that our Augusta platform—which integrates Contingent AI technology, comprehensive toxicity databases, and in vivo testing capabilities—is directly aligned with directives outlined in the recent 2027 Defense Authorization Bill. This bill emphasizes the need for a national strategy to utilize AI and biological screening to understand potential chemical threats, perfectly encapsulating the scope of our current initiatives.

Advancements in Precision Neurology

Simultaneously, Lunai Bioworks is making strides in precision neurology through our Augusta™ AI platform aimed at addressing conditions like epilepsy, Parkinson's disease, and Alzheimer’s. Our recent partnerships, including collaboration with BrainStorm Therapeutics and support from National Institutes of Health (NIH) initiatives, validate our biology-first discovery approach that is crucial in the management of these complex neurological disorders.

The challenges posed by neurological diseases make them some of the most pressing medical issues affecting millions globally. Our innovative strategy, combining extensive patient datasets with advanced AI analytics, presents opportunities that traditional methods may overlook. Thus, this segment is set to be a vital long-term value contributor for Lunai, independent of our biodefense ventures.

The Intersection of AI, Biotech, and National Security

The relevance of biodefense has become increasingly apparent among global leaders in government and technology. Recently, prominent executives from companies like Google and Microsoft, along with various national security organizations, emphasized the pressing need for enhanced regulations on synthetic biology. This concern arises from the diminishing barriers around the design of biological threats, emphasizing the need for vigilance in our field.

As we reflect on the risks posed by engineered biological agents and the possibility of pandemics—whether natural or human-induced—it is evident that the line between public health and national security continues to blur. The cost implications witnessed during the COVID pandemic only serve to exacerbate this reality. Hence, governments are ramping up investments in rapid detection and response capabilities akin to those reserved for traditional warfare.

While Lunai currently concentrates on chemical threat assessments, our AI-driven platforms are also applicable across a spectrum of biological threats. We are diligently seeking partnerships to enhance our biodefense capabilities in threat detection and countermeasure development, positioning ourselves strategically in light of increasing government focus on biological risks.

Protecting Shareholder Value Through Legal Action

In May 2026, we initiated legal proceedings in Delaware against unidentified parties alleged to have engaged in manipulative trading practices, including naked short selling. The evidence highlights suspicious trading activities, including 29.6 million shares failing to deliver—accounting for over 81% of our total shares—with trading volumes suggesting manipulation.

The court has recognized the validity of our claims and allowed for expedited discovery aimed at uncovering identities linked to these activities. Our goal is clear: to hold accountable those who have artificially suppressed our stock value and ensure a fair trading environment for all shareholders.

Looking to the Future

Today, Lunai Bioworks stands as a significantly evolved entity compared to a year ago, having established a solid foundation with our first defense contract, developed networks with premier scientific bodies, and validated our AI methodologies in both biodefense and neurology. Additionally, our ongoing litigation to address market manipulation is not just a distraction; it reflects our commitment to shareholder interests.

The convergence of artificial intelligence, biotechnology, and national security has created an exceptional strategic opportunity. As we navigate through the latter half of 2026, we remain dedicated to enhancing our platforms in biodefense and neurology, advancing our legal strategies, and building long-term value for our investors. Thank you for your unwavering support during this transformative journey.

Sincerely,

David Weinstein
Chief Executive Officer
Lunai Bioworks, Inc.